Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Clinical Phase Audit Preparation – V 2.0

Posted on By

BA-BE Studies: SOP for Clinical Phase Audit Preparation – V 2.0

Standard Operating Procedure for Clinical Phase Audit Preparation in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/100/2025
Supersedes SOP/BA-BE/100/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the process for preparing the clinical site and documentation for audits conducted during or after the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies, including internal QA audits, sponsor audits, and regulatory inspections.

2. Scope

This SOP applies to all clinical trial staff, including investigators, QA personnel, CRCs, and data managers involved in BA/BE studies at the research facility.

3. Responsibilities

  • QA Officer: Leads the audit preparation process, schedules mock audits, and ensures readiness of documentation and facility.
  • CRC: Assists with documentation collation, subject files, and query resolution.
  • PI: Ensures team cooperation, participates in audit interviews, and oversees resolution of audit findings.
  • Data Management Team: Ensures CRFs, eCRFs, and data listings are complete and up to date.
See also  BA-BE Studies: SOP for Data Entry and Source Documentation in Clinical Phase - V 2.0

4. Accountability

The QA Head is accountable for audit readiness and ensuring that all clinical activities and records meet ICH GCP, Schedule Y, and applicable sponsor-specific guidelines.

5. Procedure

5.1 Audit Notification and Planning

  1. On receipt of audit notification (or internal scheduling), initiate audit readiness activities immediately.
  2. Prepare audit schedule and assign area-wise coordinators for documentation and site readiness.

5.2 Documentation Review

  1. Ensure availability and accessibility of the following documents:
    • Signed Informed Consent Forms (ICFs)
    • Approved Protocols and Amendments
    • Ethics Committee correspondence
    • Volunteer screening and enrollment logs
    • Dosing and sample collection records
    • Adverse Event logs and management reports
    • Monitoring reports and query logs
  2. Verify CRF-to-source data consistency and resolve all outstanding data queries.

5.3 Facility Preparation

  1. Ensure restricted access areas are clearly marked and clean.
  2. Prepare audit room with:
    • Printer, copier, access to study folders (paper/electronic)
    • Seating arrangements for auditor and host
  3. Ensure IP storage, archival, sample storage areas are audit-ready.
See also  BA-BE Studies: SOP for Volunteer Identification and Screening Logs - V 2.0

5.4 Team Briefing

  1. Conduct pre-audit briefing with all study staff:
    • Explain audit process
    • Assign subject matter experts (SMEs)
    • Discuss commonly asked questions and data flow

5.5 Conducting the Audit

  1. Host to welcome auditor, provide site tour, and introduce study team.
  2. Provide requested documents promptly and track all auditor queries in Annexure-1: Audit Query Tracker.
  3. Take daily feedback from auditors and prepare summary of observations.

5.6 Post-Audit Activities

  1. Compile draft response for all observations using Annexure-2: Audit Observation Response Form.
  2. Implement CAPA where applicable and update Annexure-3: CAPA Tracking Log.
  3. Share final responses with auditor/sponsor as per defined timeline.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • QA: Quality Assurance
  • PI: Principal Investigator
  • CRC: Clinical Research Coordinator
  • CRF: Case Report Form
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Audit Query Tracker – Annexure-1
  2. Audit Observation Response Form – Annexure-2
  3. CAPA Tracking Log – Annexure-3
See also  BA-BE Studies: SOP for IEC/IRB Continuing Review Applications - V 2.0

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules
  • Sponsor Audit Requirements

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Audit Query Tracker

Date Query Description Document Referenced Status Resolved By
17/04/2025 Missing consent signature ICF-VOL-100 Resolved Sunita Reddy

Annexure-2: Audit Observation Response Form

Observation Root Cause Corrective Action Preventive Action Owner
Incomplete AE Log Late entry Entry updated Real-time log review CRC

Annexure-3: CAPA Tracking Log

CAPA No. Description Implemented On Verified By
CAPA-100 Retraining on AE logging 18/04/2025 QA Officer

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial SOP Process Setup QA Head
17/04/2025 2.0 Annexures and audit checklists added GCP Inspection Readiness QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Creams: SOP for Analyzing Moisture Content in Creams – V 2.0
Next Post: API Manufacturing: SOP for Maintenance of Drying and Milling Logs – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version